JP2025502064A5 - - Google Patents

Info

Publication number
JP2025502064A5
JP2025502064A5 JP2024540893A JP2024540893A JP2025502064A5 JP 2025502064 A5 JP2025502064 A5 JP 2025502064A5 JP 2024540893 A JP2024540893 A JP 2024540893A JP 2024540893 A JP2024540893 A JP 2024540893A JP 2025502064 A5 JP2025502064 A5 JP 2025502064A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
compound according
aforementioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502064A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/010331 external-priority patent/WO2023133284A2/en
Publication of JP2025502064A publication Critical patent/JP2025502064A/ja
Publication of JP2025502064A5 publication Critical patent/JP2025502064A5/ja
Pending legal-status Critical Current

Links

JP2024540893A 2022-01-06 2023-01-06 フリードライヒ運動失調症を治療するための化合物及び方法 Pending JP2025502064A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263297090P 2022-01-06 2022-01-06
US63/297,090 2022-01-06
US202263382854P 2022-11-08 2022-11-08
US63/382,854 2022-11-08
PCT/US2023/010331 WO2023133284A2 (en) 2022-01-06 2023-01-06 Compounds and methods for treating friedreich's ataxia

Publications (2)

Publication Number Publication Date
JP2025502064A JP2025502064A (ja) 2025-01-24
JP2025502064A5 true JP2025502064A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=87074158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540893A Pending JP2025502064A (ja) 2022-01-06 2023-01-06 フリードライヒ運動失調症を治療するための化合物及び方法

Country Status (14)

Country Link
US (1) US20250109132A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460302A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502064A (cg-RX-API-DMAC7.html)
KR (1) KR20240138079A (cg-RX-API-DMAC7.html)
AU (1) AU2023205889A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246468A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002029A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010651A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240321A (cg-RX-API-DMAC7.html)
IL (1) IL314006A (cg-RX-API-DMAC7.html)
MX (1) MX2024008474A (cg-RX-API-DMAC7.html)
PE (1) PE20241730A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334148A (cg-RX-API-DMAC7.html)
WO (1) WO2023133284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2025076181A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
EP4788669A1 (en) * 2023-10-03 2026-08-12 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
WO2025076219A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2015053413A1 (ja) * 2013-10-11 2015-04-16 千葉県 ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤
US11759533B2 (en) * 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
JP7465945B2 (ja) * 2019-07-02 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Bet阻害剤としてのヘテロ環式化合物
CA3204523A1 (en) * 2021-01-08 2022-07-14 Aseem Ansari Methods and compounds for treating friedreich's ataxia

Similar Documents

Publication Publication Date Title
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2023098946A5 (cg-RX-API-DMAC7.html)
JP2021098728A5 (cg-RX-API-DMAC7.html)
JP2021191784A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2025013344A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2024156774A5 (cg-RX-API-DMAC7.html)
HRP20150838T1 (hr) Sastavi koji sadrže modulatore receptora sfingozin 1 fosfata (s1p)
JP2017057230A5 (cg-RX-API-DMAC7.html)
JP2025161856A5 (cg-RX-API-DMAC7.html)
JP2020532547A5 (cg-RX-API-DMAC7.html)
JP2006526590A5 (cg-RX-API-DMAC7.html)
JP2006522006A5 (cg-RX-API-DMAC7.html)
JP2020508338A5 (cg-RX-API-DMAC7.html)
JP2015524444A5 (cg-RX-API-DMAC7.html)
JP2021512098A5 (cg-RX-API-DMAC7.html)
JP2017222722A5 (cg-RX-API-DMAC7.html)
JP2022513449A5 (cg-RX-API-DMAC7.html)
JP2007520506A5 (cg-RX-API-DMAC7.html)
JP2018521121A5 (cg-RX-API-DMAC7.html)
JP2024541569A5 (cg-RX-API-DMAC7.html)
JP2019533660A5 (cg-RX-API-DMAC7.html)
JP2023531675A5 (cg-RX-API-DMAC7.html)